TRIP13 overexpression is also associated with chemotherapy resistance, promotes the progression of head and neck cancer, breast cancer, and colorectal cancer, and is significantly associated with poor prognosis in patients (Banerjee et al., 2014; Wang et al., 2014; Sheng et al., 2018). The gene discussed is TRIP13; the disease is breast carcinoma.